<DOC>
	<DOCNO>NCT00217399</DOCNO>
	<brief_summary>Sorafenib may stop growth tumor cell block blood flow tumor block enzyme need cell growth . Estradiol cause growth breast cancer . Hormone therapy use anastrozole may fight breast cancer block use estradiol tumor cell . Sometimes hormone therapy give , stop growth tumor cell . The tumor say resistant hormone therapy . Giving sorafenib together anastrozole may reduce drug resistance allow tumor cell kill . This phase I/II trial study side effect best dose sorafenib give combination anastrozole see well work treat postmenopausal woman metastatic breast cancer .</brief_summary>
	<brief_title>Sorafenib Anastrozole Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine clinical benefit rate sorafenib combination anastrazole woman estrogen receptor- and/or progesterone receptor-positive metastatic breast cancer . II . Determine recommend phase II dose sorafenib administer anastrozole patient . SECONDARY OBJECTIVES : I . Determine toxic effect regimen patient . II . Determine change Raf-MAPK VEGF-signaling pathway tumor tissue stroma treatment regimen patient . OUTLINE : This multicenter , dose-escalation study sorafenib . PHASE I : Patients receive oral sorafenib twice daily oral anastrozole daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sorafenib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . A minimum 6 patient treated MTD . PHASE II : Patients receive sorafenib MTD anastrozole phase I . After completion study treatment , patient follow every 4-8 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer Metastatic disease Measurable disease , define &gt; =1 unidimensionally measurable lesion , include &gt; = 1 following : Lesion &gt; = 10 mm CT scan ( 5 mm section ) Lesion &gt; = 20 mm CT scan MRI ( 10 mm section ) Bone disease &gt; = 10 mm MRI Lytic bone lesion &gt; = 10 mm CT scan ( 5 mm section ) OR &gt; = 20 mm plain film CT scan ( 10 mm section ) Lesion &gt; = 10 mm physical exam Patients must receive &gt; = 1 prior aromatase inhibitor either adjuvant metastatic setting must either disease recurrence disease progression prior aromatase inhibitor therapy No brain metastasis diagnose within past 6 month OR previously untreated brain metastasis Estrogen receptorpositive and/or progesterone receptorpositive , define &gt; 1 % stain immunohistochemistry &gt; 10 fmol/mg protein radioligand dextrancoated steroid bind assay Postmenopausal , define 1 following : Prior bilateral oophorectomy No menses &gt; = 12 month patient intact uterus Folliclestimulating hormone ( FSH ) postmenopausal range patient &lt; 60 year age prior hysterectomy amenorrheic &gt; = 3 month Age &gt; = 60 year Pre perimenopausal patient receive monthly injection goserelin dose 3.6 mg eligible ECOG 02 More 3 month Absolute neutrophil count &gt; = 1,500/mm3 Platelet count &gt; = 100,000/mm3 No bleed diathesis Bilirubin = &lt; 1.5 time upper limit normal ( ULN AST ALT = &lt; 2.5 time ULN Systolic blood pressure ( BP ) &lt; 150 mm Hg diastolic BP &lt; 100 mm Hg least one reading prior study entry No uncontrolled hypertension None follow within past 6 month : Symptomatic congestive heart failure Unstable angina pectoris Myocardial infarction Cardiac arrhythmia hemodynamic compromise Not pregnant nursing Able swallow oral medication No known HIV positivity No ongoing active infection No psychiatric illness social situation would preclude study compliance No active invasive malignancy within past 5 year except nonmelanoma skin cancer treat carcinoma situ cervix No uncontrolled illness More 4 week since prior chemotherapy No 2 prior chemotherapy regimens metastatic disease At least 8 week since prior anastrozole therapy Concurrent steroid allow dose stable More 4 week since prior radiotherapy More 4 week since prior major surgery Recovered prior therapy No prior sorafenib No concurrent therapeutic anticoagulation Concurrent prophylactic anticoagulation ( i.e. , lowdose warfarin ) venous arterial access device allow provided PT PTT = &lt; 1.5 time ULN No concurrent agent may interact sorafenib , include follow : Hypericum perforatum ( St. John 's wort ) Rifampin P450 CYP3A4 enzymeinducing anticonvulsant ( e.g. , phenytoin , carbamazepine , phenobarbital ) No concurrent investigational agent estrogen receptor status unknown history myocardial infarction within 6 month performance status 3 performance status 4 premenopausal progesterone receptor status unknown HIV positive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>